We are pleased to announce that we have entered into a strategic partnership with Gilead Sciences to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products. WuXi’s Lab Testing Division (LTD) will equip and operate a dedicated, fully cGMP-compliant analytical testing facility in Shanghai with dedicated staff. The opening of this analytical and stability testing center is an important milestone in the ongoing long-term relationship between Gilead and WuXi. We are determined to enable our innovative partners like Gilead through our open-access R&D platform, and we are honored to help advance some of the most innovative medicines faster to patients.
Related Links: